Trial · NCT05327088
Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia
NCT05327088, Phase 2, Completed, Ain Shams University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia. Trials, record NCT05327088. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05327088
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia
- NCT number
- NCT05327088
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 64 participants, actual
- Lead sponsor
- Ain Shams University
- Conditions
- Epidural Anesthesia, Labor Pain
- Interventions
- Dexmedetomidine, Nalbuphine
- First posted
- 2022-04-14
- Last updated
- 2022-04-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | change in VAS score for pain before analgesia and every 30 minutes after analgesia | before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes) | The visual analog scale (VAS) is a tool widely used to measure pain. A patient is asked to indicate his/her perceived pain intensity along a 100 mm (10 cm) horizontal line, and this rating is then measured from the left edge (=VAS score). The VAS score correlates well with acute pain levels (Myles et al., 1999). Using a ruler, the score is determined by measuring the distance (cm) on the 10-cm line between the no pain anchor and the patients mark, providing a range of scores from 010. A higher score indicates greater pain intensity. |
| Secondary | change in Heart rate before analgesia and every 30 minutes after analgesia | before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes) | Monitored and recorded |
| Secondary | change in arterial blood pressure before analgesia and every 30 minutes after analgesia | before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes) | Monitored and recorded |
| Secondary | change in SpO2 before analgesia and every 30 minutes after analgesia | before analgesia and 30 minutes after analgesia and then every 30 minute as long as the epidural catheter is inserted (up to 360 minutes) | Monitored and recorded |
| Secondary | Duration of active phase of 1st stage of labor | from 100 minutes to 300 minutes | The duration of active phase of 1st stage of labor varies from one to the other |
| Secondary | Duration of 2nd stage of labor | from 30 minutes to 200 minutes | The duration of 2nd stage of labor varies from one to the other |
| Secondary | Duration of 3rd stage of labor | from 5 minutes to 15 minutes | The duration of 3rd stage of labor varies from one to the other |
| Secondary | Neonatal condition: APGAR score at 1 and 5 min after the birth | At 1 minute and 5 minutes after birth | to check if any of the study drugs can deteriorate the neonatal condition |
| Secondary | The adverse reactions: itching, nausea, vomiting, bradycardia and hypotension | As long as the epidural catheter is inserted (up to 360 minutes) | These adverse reaction can occur after administration of the interventional drugs |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05327088
GET https://conductscience.org/api/trials/v1/NCT05327088/registered